Acrivon Therapeutics chief legal officer sells $585 in stock

Chief Legal Officer Mary Miller of Acrivon Therapeutics sold 294 shares of the company's common stock on October 5, 2026, as disclosed in an SEC filing. The shares were sold at $1.99 each, generating a total of $585. This sale was automatic, triggered by the vesting of restricted stock units to meet tax withholding obligations. The reported price represents an average from a sale of 337 shares by Miller, including tax liability for several employees.

The funds were distributed equitably among the recipients. Currently, ACRV shares are trading at $1.88, marking an 8.3% decline in the past week, but a 28% increase over six months. Pro analysis indicates the stock is undervalued at these levels, and ACRV is listed among the Most Undervalued equities. Miller, post-transaction, holds 81,715 shares of Acrivon Therapeutics.